Given that AKAP12 was negatively linked with anti-VEGF therapy sensitivity in OV, GBM, LUSC, and CRC, we proposed that AKAP12 might promote resistance via the recruitment and activation of CAFs. This evidence concerns the gene AKAP12 and colorectal carcinoma.